Theravance Biopharma, Mylan Reach Settlement Over Inhalation Drug Yupelri
By Sabela Ojea
Theravance Biopharma, Mylan Ireland and Mylan Specialty have entered into a settlement agreement with Teva Pharmaceutical Industries over their Yupelri inhalation drug, according to a Securities and Exchange Commission filing.
The biopharmaceutical company on Monday said the parties agreed to grant Teva a royalty-free, non-exclusive, non-transferable license to manufacture and market Teva's generic version of Yupelri in the U.S. on or after the licensed launch date of April 23, 2039.
The settlement is subject to review by the Justice Department and the Federal Trade Commission.
The companies didn't disclose financial details on the settlement.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 30, 2023 18:50 ET (22:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?